



**IMPORTANT INFORMATION FOR HEALTHCARE PROFESSIONALS**  
**SUPPLY OF TRULICITY® (DULAGLUTIDE) 1.5 MG IN AUSTRALIA**

21 June 2022

Dear Registered Pharmacist,

Eli Lilly Australia (Lilly) has been and is continuing to experience an unanticipated increase in demand for TRULICITY® (dulaglutide) 1.5 mg, a once-weekly GLP-1 RA for adults with Type 2 diabetes (T2D).<sup>1</sup> The increase in demand is driven by the supply issues of another pharmaceutical company's T2D medication which are published on the Therapeutic Goods Administration (TGA) medicine shortage database.<sup>2</sup> This increase in demand is outside Lilly's control.

On 21 June 2022 Trulicity was also listed on the TGA medicine shortage database with Limited Availability expected until 31 August 2022.<sup>2</sup>

While stock of Trulicity 1.5 mg is still available in Australia, increased demand may lead to temporary delays, interruptions and/or shortages in stock available through wholesalers and at pharmacies.

To minimise interruptions or delays in treatment for patients, Lilly is working with our partners in endeavouring to distribute available stock across the supply chain as equitably as possible and with a focus on patients prescribed Trulicity for T2D.

During this period, Lilly recommends that pharmacists consider the following to help manage access to Trulicity for patients with T2D:

- Limit dispensing to one (1) month of medication at a time.
- Remind patients to contact the pharmacy as early as possible to have their prescription filled, so that timely supply can be organised. Encourage your customers to leave their prescription with their regular pharmacy.
- Order stock of Trulicity through your usual wholesaler/s.

Lilly is in frequent contact with wholesalers and together we are closely monitoring stock levels through this period of increased demand, which remains dynamic. New shipments into Australia are anticipated weekly and replenishment of the supply chain is ongoing.

We recognise the inconvenience these disruptions may cause and will provide relevant updates via [lilly.com.au](http://lilly.com.au). For any further information or support, please contact our Lilly Australia Medical Information team on 1800 454 559/ 1800 4 LILLY.

Yours Sincerely,

**Benjamin Basil**

President & General Manager

Australia, New Zealand & North Asia-Pacific

References: 1.Trulicity Approved Product Information, July 2020 2.Australian Department of Health, Therapeutic Goods Administration, available at

<http://apps.tga.gov.au/Prod/msi/search?shortagetype=All>, last accessed 21 June 2022

Abbreviation: GLP-1 RA, glucagon like peptide 1 receptor agonist

**PBS Information:** Authority Required (STREAMLINED). Type 2 diabetes. Criteria Apply.  
Refer to PBS Schedule for full Authority Required Information.

Please refer to the full product information before prescribing. Full product information can be accessed at [www.lilly.com.au/en/products](http://www.lilly.com.au/en/products) or on request by calling 1800 454 559.

**INDICATIONS** – TRULICITY is indicated for adult patients with Type 2 diabetes as 1) an adjunct to diet and exercise to improve glycaemic control; and 2) as an adjunct to standard of care therapy to reduce the risk of major adverse cardiovascular events in those with either established cardiovascular disease or multiple risk factors for cardiovascular disease. **CONTRAINDICATIONS** – Hypersensitivity to dulaglutide or any of the excipients. **PRECAUTIONS** – should not be used in patients with Type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis; severe gastrointestinal disease – not recommended; acute pancreatitis – discontinue treatment if suspected; hypoglycaemia – combining treatment with sulfonylurea or insulin may increase risk; congestive heart failure – limited therapeutic experience. Use in Pregnancy Category B3. **ADVERSE EFFECTS Clinical Trials Experience** – Very Common ( $\geq 10\%$ ) gastrointestinal disorders (nausea, vomiting and diarrhoea), hypoglycaemia (in combination with insulin non-/secretagogues and/or insulin); Common ( $\geq 1$  and  $< 10\%$ ) abdominal pain, decreased appetite, dyspepsia, fatigue, hypoglycaemia (as monotherapy), immunogenicity, atrial fibrillation. **DOSAGE AND ADMINISTRATION** – Dosage: Adults ( $\geq 18$  years): 1.5 mg once weekly, at any time of day, independently of meals. Elderly Patients ( $\geq 65$  years): dose adjustment not required. Children and adolescents ( $< 18$  years): safety and effectiveness have not been established. Renal Impairment: no dose adjustment is required in mild, moderate or severe renal impairment; not recommended in end-stage renal disease. Hepatic Impairment: no dose adjustment required. Administration: subcutaneous injection in the abdomen, thigh or upper arm. Should not be administered intravenously or intramuscularly. Single-use in one patient only. Discard the pen once the injection is completed.

Please review full PI before prescribing. Full PI is available on request from Eli Lilly. Eli Lilly Australia Pty Ltd, 112 Wharf Road, West Ryde NSW 2114. Phone 1800 454 559. Based on PI approved 14 July 2020.

TRULICITY® is a registered trademark of Eli Lilly and Company. PP-DG-AU-0854 June 2022

The Lilly logo is written in a red, cursive script font.